Anika Therapeutics | ANIK - Gross Profit On Sales


Anika Therapeutics reported $19.18M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
Agenus USD 33.74M 468K Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 75.25M 1.52M Jun/2026
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 356.19M 99.73M Jun/2026
Integra LifeSciences USD 215.97M 2.77M Jun/2026
Intrexon USD -297K 167K Jun/2024
J&J USD 18.55B 1.31B Jun/2026
Karyopharm Therapeutics USD 33.72M 1.13M Mar/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merit Medical Systems USD 215.17M 30.37M Jun/2026
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.71B 602M Jun/2026
Smith & Nephew USD 2.09B 117M Dec/2025
Stryker USD 4.5B 688M Jun/2026
Veracyte USD 108.55M 7.39M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026
Zimmer Biomet Holdings USD 1.36B 149.4M Jun/2026